Recent research have converged on the intersection of GLP-1|GIP|GCGR stimulant therapies and dopaminergic signaling. While GCGR activators are increasingly employed for addressing type 2 diabetes mellitus, their potential impacts on reward circuits, specifically governed by DA networks, are receiving substantial interest. This article details a … Read More